CFO
Esperion Therapeutics, Inc.
Equibles does not estimate personal net worth.
Ben Halladay is recorded as CFO at Esperion Therapeutics, Inc.. Esperion Therapeutics, Inc. reported in an 8-K filed November 16, 2022 that Ben Halladay was appointed Chief Financial Officer, effective November 16, 2022. Ben Halladay has spoken on 3 earnings calls across 1 company, most recently for Esperion Therapeutics, Inc. on May 6, 2025. Esperion Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
“Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Financial Planning and Analysis, effective as of today.”
“Our first quarter 2025 financial results can be found in the press release we issued this morning and more detail will be included in our upcoming 10-Q. First quarter 2025 total revenue was $65 million, a decrease of 53%.”
“As Sheldon mentioned earlier, we continue to build and solidify the foundation of our business, and this year has been a banner year for taking the right steps that will allow us to grow and succeed in the long-term.”
“Before I get into the details of the quarterly results, I want to highlight the transformational transaction we completed at the end of the quarter.”
Esperion Therapeutics, Inc.
CFO
Source not stated
Esperion Therapeutics, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Esperion Therapeutics, Inc. Q1 FY2025 Earnings Call
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. Q3 FY2024 Earnings Call
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. Q2 FY2024 Earnings Call
Esperion Therapeutics, Inc.
